{"id":"https://openalex.org/W2139757550","doi":"https://doi.org/10.1161/hypertensionaha.107.108845","title":"Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats","display_name":"Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W2139757550","doi":"https://doi.org/10.1161/hypertensionaha.107.108845","mag":"2139757550","pmid":"https://pubmed.ncbi.nlm.nih.gov/18490518"},"language":"en","primary_location":{"id":"doi:10.1161/hypertensionaha.107.108845","doi":"https://doi.org/10.1161/hypertensionaha.107.108845","is_oa":false,"landing_page_url":"https://doi.org/10.1161/hypertensionaha.107.108845","pdf_url":null,"source":{"id":"https://openalex.org/S67880631","display_name":"Hypertension","issn_l":"0194-911X","issn":["0194-911X","1524-4563"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hypertension","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2139757550"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://hdl.handle.net/1765/29400","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"David L. Feldman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"David L. Feldman","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Liang Jin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Liang Jin","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hong Xuan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Hong Xuan","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053820401","display_name":"Aur\u00e9lie Contrepas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Aurelie Contrepas","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102618055","display_name":"Yinong Zhou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Yinong Zhou","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079589473","display_name":"Randy L. Webb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Randy L. Webb","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113738787","display_name":"Dominik N. Mueller","orcid":"https://orcid.org/0000-0003-3650-5644","observed_orcids":["https://orcid.org/0000-0003-3650-5644"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Dominik N. Mueller","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060544098","display_name":"Sandra Feldt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Sandra Feldt","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013164997","display_name":"Frederick Cumin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Frederick Cumin","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077521045","display_name":"Wieslawa M. Maniara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Wieslawa Maniara","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011594393","display_name":"Elke Persohn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Elke Persohn","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088261636","display_name":"Helmut Schuetz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Helmut Schuetz","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046295598","display_name":"A.H. Jan Danser","orcid":"https://orcid.org/0000-0002-5052-3585","observed_orcids":["https://orcid.org/0000-0002-5052-3585"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"A.H. Jan Danser","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110201052","display_name":"Genevi\u00e8ve Nguyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I205582932","display_name":"Max Delbr\u00fcck Center","ror":"https://ror.org/04p5ggc03","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I205582932"]},{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","DE","FR","NL"],"is_corresponding":false,"raw_author_name":"Genevieve Nguyen","raw_affiliation_strings":["From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","Inserm Unit 833 (A.C., G.N.), Paris, France","Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Novartis Institutes for Biomedical Research (D.L.F., L.J., H.X., Y.Z., R.L.W., F.C., W.M.), E. Hanover, NJ and Cambridge, Mass; Inserm Unit 833 (A.C., G.N.), Paris, France; Chaire de Me\u0301decine Expe\u0301rimentale (A.C., G.N.), Colle\u0300ge de France, Paris, France; Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany; Novartis Pharma AG (E.P., H.S.), Basel, Switzerland; and the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I205582932","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Inserm Unit 833 (A.C., G.N.), Paris, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Max-Delbruck-Center (D.N.M., S.F.), Berlin-Buch, Germany","institution_ids":["https://openalex.org/I205582932"]},{"raw_affiliation_string":"Novartis Pharma AG (E.P., H.S.), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"the Department of Pharmacology (A.H.J.D.), Erasmus MC, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":31.0889,"has_fulltext":false,"cited_by_count":283,"citation_normalized_percentile":{"value":0.99765872,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"52","issue":"1","first_page":"130","last_page":"136"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9506999850273132,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.9506999850273132,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.043800000101327896,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aliskiren","display_name":"aliskiren","score":1.0},{"id":"https://openalex.org/keywords/renin-inhibitors","display_name":"renin inhibitors","score":0.7570000290870667},{"id":"https://openalex.org/keywords/diabetic-nephropathy","display_name":"diabetic nephropathy","score":0.8920000195503235},{"id":"https://openalex.org/keywords/prorenin-receptor","display_name":"prorenin receptor","score":0.9010000228881836},{"id":"https://openalex.org/keywords/prorenin","display_name":"prorenin","score":0.8309999704360962},{"id":"https://openalex.org/keywords/renin-angiotensin-system","display_name":"renin-angiotensin system","score":0.8069999814033508},{"id":"https://openalex.org/keywords/blood-pressure","display_name":"blood pressure","score":0.7110000252723694},{"id":"https://openalex.org/keywords/albuminuria","display_name":"albuminuria","score":1.0},{"id":"https://openalex.org/keywords/renal-protection","display_name":"renal protection","score":0.8960000276565552},{"id":"https://openalex.org/keywords/streptozotocin-induced-diabetes","display_name":"streptozotocin-induced diabetes","score":0.8999999761581421},{"id":"https://openalex.org/keywords/transforming-growth-factor-beta","display_name":"TGF-beta","score":0.796999990940094},{"id":"https://openalex.org/keywords/type-i-collagen","display_name":"type I collagen","score":0.9549999833106995},{"id":"https://openalex.org/keywords/mesangial-cells","display_name":"mesangial cells","score":0.8149999976158142},{"id":"https://openalex.org/keywords/extracellular-signal-regulated-kinase-1-2","display_name":"ERK1/ERK2","score":0.9150000214576721}],"concepts":[{"id":"https://openalex.org/C2779838083","wikidata":"https://www.wikidata.org/wiki/Q414904","display_name":"Aliskiren","level":4,"score":0.9924699664115906},{"id":"https://openalex.org/C2777425892","wikidata":"https://www.wikidata.org/wiki/Q409255","display_name":"Renin inhibitor","level":4,"score":0.8825230598449707},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.7818014621734619},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7597560286521912},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7465419769287109},{"id":"https://openalex.org/C138976137","wikidata":"https://www.wikidata.org/wiki/Q7201790","display_name":"Plasma renin activity","level":4,"score":0.589296817779541},{"id":"https://openalex.org/C2779922275","wikidata":"https://www.wikidata.org/wiki/Q1129105","display_name":"Diabetic nephropathy","level":3,"score":0.5741450786590576},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5416520237922668},{"id":"https://openalex.org/C2776174234","wikidata":"https://www.wikidata.org/wiki/Q974792","display_name":"Albuminuria","level":3,"score":0.45094725489616394},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.42236316204071045},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.3420998454093933},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3339449465274811},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.30380141735076904}],"mesh":[{"descriptor_ui":"D000092502","descriptor_name":"Renin Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000093342","descriptor_name":"Prorenin Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000419","descriptor_name":"Albuminuria","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D000419","descriptor_name":"Albuminuria","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000419","descriptor_name":"Albuminuria","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003921","descriptor_name":"Diabetes Mellitus, Experimental","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003921","descriptor_name":"Diabetes Mellitus, Experimental","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003921","descriptor_name":"Diabetes Mellitus, Experimental","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003928","descriptor_name":"Diabetic Nephropathies","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D005650","descriptor_name":"Fumarates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005650","descriptor_name":"Fumarates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011956","descriptor_name":"Receptors, Cell Surface","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D011956","descriptor_name":"Receptors, Cell Surface","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D011956","descriptor_name":"Receptors, Cell Surface","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012083","descriptor_name":"Renin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015870","descriptor_name":"Gene Expression","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016212","descriptor_name":"Transforming Growth Factor beta","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016212","descriptor_name":"Transforming Growth Factor beta","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D024042","descriptor_name":"Collagen Type I","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D024042","descriptor_name":"Collagen Type I","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D024061","descriptor_name":"Collagen Type III","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D024061","descriptor_name":"Collagen Type III","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D024141","descriptor_name":"Collagen Type IV","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D024141","descriptor_name":"Collagen Type IV","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":7,"locations":[{"id":"doi:10.1161/hypertensionaha.107.108845","doi":"https://doi.org/10.1161/hypertensionaha.107.108845","is_oa":false,"landing_page_url":"https://doi.org/10.1161/hypertensionaha.107.108845","pdf_url":null,"source":{"id":"https://openalex.org/S67880631","display_name":"Hypertension","issn_l":"0194-911X","issn":["0194-911X","1524-4563"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hypertension","raw_type":"journal-article"},{"id":"pmid:18490518","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18490518","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hypertension (Dallas, Tex. : 1979)","raw_type":"Journal Article"},{"id":"pmh:oai:pure.eur.nl:openaire_cris_publications/98bb4c1a-c66d-459d-82fa-1cd3609decbf","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/98bb4c1a-c66d-459d-82fa-1cd3609decbf","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Feldman, DL, Jin, L, Xuan, H, Contrepas, A, Zhou, YN, Webb, RL, Mueller, DN, Feldt, S, Cumin, F, Maniara, W, Persohn, E, Schuetz, H, Danser, J & Nguyen, G 2008, 'Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats', Hypertension, vol. 52, no. 1, pp. 130-136. https://doi.org/10.1161/HYPERTENSIONAHA.107.108845","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:eur:oai:pure.eur.nl:publications/98bb4c1a-c66d-459d-82fa-1cd3609decbf","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/98bb4c1a-c66d-459d-82fa-1cd3609decbf","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hypertension, 52(1), 130 - 136. Lippincott Williams & Wilkins","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:eur:oai:repub.eur.nl:29400","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/1765/29400","pdf_url":null,"source":{"id":"https://openalex.org/S4377196287","display_name":"RePub (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hypertension, 52(1), 130 - 136","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:edoc.mdc-berlin.de:9556","doi":null,"is_oa":false,"landing_page_url":"http://edoc.mdc-berlin.de/9556/","pdf_url":null,"source":{"id":"https://openalex.org/S4306400224","display_name":"MDC Repository (Max-Delbrueck-Center for Molecular Medicine)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I149899117","host_organization_name":"Max Planck Society","host_organization_lineage":["https://openalex.org/I149899117"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"},{"id":"pmh:oai:repub.eur.nl:29400","doi":null,"is_oa":false,"landing_page_url":"https://repub.eur.nl/pub/29400","pdf_url":null,"source":{"id":"https://openalex.org/S4377196287","display_name":"RePub (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hypertension vol. 52 no. 1, pp. 130-136","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:eur:oai:repub.eur.nl:29400","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/1765/29400","pdf_url":null,"source":{"id":"https://openalex.org/S4377196287","display_name":"RePub (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hypertension, 52(1), 130 - 136","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1594509828","https://openalex.org/W1976070473","https://openalex.org/W1977810373","https://openalex.org/W1979771115","https://openalex.org/W1990301821","https://openalex.org/W2003350706","https://openalex.org/W2008494063","https://openalex.org/W2015569360","https://openalex.org/W2017268330","https://openalex.org/W2019310839","https://openalex.org/W2049491194","https://openalex.org/W2056976690","https://openalex.org/W2061624989","https://openalex.org/W2068417672","https://openalex.org/W2083898560","https://openalex.org/W2101668704","https://openalex.org/W2105577802","https://openalex.org/W2120390384","https://openalex.org/W2127749087","https://openalex.org/W2128520582","https://openalex.org/W2130310565","https://openalex.org/W2135439806","https://openalex.org/W2146227799","https://openalex.org/W2151295696","https://openalex.org/W2163957982","https://openalex.org/W2166710642","https://openalex.org/W2170415924","https://openalex.org/W2407613771","https://openalex.org/W2615684303","https://openalex.org/W4252397535"],"related_works":["https://openalex.org/W1590651239","https://openalex.org/W1561622928","https://openalex.org/W2273192606","https://openalex.org/W2076608224","https://openalex.org/W2315397902","https://openalex.org/W2027087508","https://openalex.org/W2117703887","https://openalex.org/W2062255908","https://openalex.org/W2008494063","https://openalex.org/W2114785494"],"abstract_inverted_index":{"The":[0,170,185],"aim":[1],"of":[2,10,26,48,124,136,154,168,179,217],"this":[3,222],"study":[4],"was":[5,159],"to":[6,45,105,117,126,164,213],"explore":[7],"the":[8,11,24,29,34,46,54,127,134,155,165,174,196,208,215,218],"effects":[9,178],"renin":[12,32,142,223],"inhibitor":[13],"aliskiren":[14,27,39,67,114,147,162,180,188],"in":[15,22,53,98,181,191],"streptozotocin-diabetic":[16],"TG(mRen-2)27":[17,65],"rats.":[18],"Furthermore,":[19],"we":[20],"investigated":[21],"vitro":[23],"effect":[25],"on":[28],"interactions":[30],"between":[31,38],"and":[33,37,40,56,81,87,101,176,199],"(pro)renin":[35,95,128,156,197],"receptor":[36,96,198],"prorenin.":[41,169],"Aliskiren":[42,93],"distributed":[43],"extensively":[44],"kidneys":[47],"normotensive":[49],"(non)diabetic":[50],"rats,":[51,66],"localizing":[52],"glomeruli":[55],"vessel":[57],"walls":[58],"after":[59],"2":[60],"hours":[61],"exposure.":[62],"In":[63,110],"diabetic":[64,183],"(10":[68],"or":[69,150],"30":[70],"mg/kg":[71],"per":[72],"day,":[73],"10":[74,118],"weeks)":[75],"lowered":[76],"blood":[77],"pressure,":[78],"prevented":[79],"albuminuria,":[80],"suppressed":[82],"renal":[83],"transforming":[84],"growth":[85],"factor-beta":[86],"collagen":[88],"I":[89],"expression":[90,97,153,194],"versus":[91],"vehicle.":[92],"reduced":[94],"glomeruli,":[99],"tubules,":[100],"cortical":[102],"vessels":[103],"compared":[104],"vehicle":[106],"(in":[107],"situ":[108],"hybridization).":[109],"human":[111],"mesangial":[112],"cells,":[113],"(0.1":[115],"micromol/L":[116],"micromol/L)":[119],"did":[120,131],"not":[121],"inhibit":[122],"binding":[123],"(125)I-renin":[125],"receptor,":[129],"nor":[130],"it":[132,201],"alter":[133],"activation":[135],"extracellular":[137],"signal-regulated":[138],"kinase":[139],"1/2":[140],"by":[141,221],"(20":[143],"nmol/L)":[144,149],"preincubated":[145],"with":[146],"(100":[148],"affect":[151],"gene":[152,193],"receptor.":[157],"Evidence":[158],"obtained":[160],"that":[161,187,200],"binds":[163],"active":[166],"site":[167],"above":[171],"results":[172],"demonstrate":[173],"antihypertensive":[175],"renoprotective":[177],"experimental":[182],"nephropathy.":[184],"evidence":[186],"can":[189],"reduce":[190],"vivo":[192],"for":[195,210],"may":[202],"block":[203],"prorenin-induced":[204],"angiotensin":[205],"generation":[206],"supports":[207],"need":[209],"additional":[211],"work":[212],"reveal":[214],"mechanism":[216],"observed":[219],"renoprotection":[220],"inhibitor.":[224]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":18},{"year":2013,"cited_by_count":25},{"year":2012,"cited_by_count":44}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}